HIV/AIDS-related deaths have fallen to their lowest level in more than 40 years as a result of the fight against the virus.

Global deaths from AIDS have dropped to their lowest levels in more than 30 years, in part due to efforts to fight HIV. But U ...

UNAIDS emphasizes that every dollar invested in the HIV response not only saves lives but strengthens health systems and promotes broader development goals. Since the start of the epidemic, 26.9 ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Today, Pride is still an uprising. Keeping HIV awareness and prevention at the heart of Pride Month deepens its mission and ...

Borey and Sophia are among the first clients in Cambodia to begin long-acting injectable Cabotegravir (CAB-LA), a PrEP ...

Tens of thousands of people suffer needless heart attacks and strokes every year because they aren't taking ...

UNAIDS statistics indicate that adolescent girls and young women (AGYW) aged 15-24 years continue to face a significant risk of HIV acquisition.

The Statistical Center for HIV/AIDS Research and Prevention (SCHARP), located at Fred Hutch Cancer Center, is a statistical and data management center (SDMC) dedicated to supporting investigators who ...

The US Food and Drug Administration (FDA) approved Yeztugo, a long-awaited semi-annual injectable treatment for the ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.